| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00069-4026-25 | 00069-4026 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 17, 2014 | Feb 28, 2026 | In Use |
| 70255-0020-01 | 70255-0020 | Encorafenib | BRAFTOVI | 50.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Jun 27, 2018 | Mar 13, 2019 | In Use |
| 63304-0096-30 | 63304-0096 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 5, 2019 | In Use | |
| 58468-0170-01 | 58468-0170 | Fludarabine | Fludara | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jul 29, 2010 | Mar 9, 2012 | No Longer Used | |
| 83831-0101-02 | 83831-0101 | Docetaxel | DOCIVYX | 20.0 mg/2mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 9, 2024 | In Use | |
| 68001-0661-06 | 68001-0661 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 30, 2025 | In Use | |
| 76282-0789-58 | 76282-0789 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 14, 2025 | In Use | |
| 00378-5264-14 | 00378-5264 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 29, 2016 | Feb 28, 2018 | No Longer Used |
| 72237-0101-02 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jul 10, 2019 | In Use | |
| 00085-1519-05 | 00085-1519 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 2, 2012 | In Use | |
| 63323-0763-50 | 63323-0763 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 20, 2009 | In Use | |
| 63323-0192-02 | 63323-0192 | Fludarabine Phosphate | Fludarabine | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov 16, 2007 | In Use | |
| 00069-0507-60 | 00069-0507 | CRIZOTINIB | Xalkori | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, HGFR, ROS1, RON | Oral | Nov 20, 2023 | In Use | |
| 00093-7663-56 | 00093-7663 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | In Use | |
| 68001-0350-68 | 68001-0350 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 25, 2018 | May 26, 2018 | In Use |
| 45963-0613-89 | 45963-0613 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 13, 2018 | Aug 31, 2021 | No Longer Used |
| 75834-0132-14 | 75834-0132 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 7, 2021 | In Use | |
| 16571-0820-41 | 16571-0820 | Temozolomide | TEMOZOLOMIDE | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
| 62484-0020-02 | 62484-0020 | Purixan | Purixan | 20.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Oral | Apr 28, 2014 | In Use | |
| 00378-1201-78 | 00378-1201 | Sorafenib | Sorafenib Tosylate | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF | Oral | Jun 1, 2022 | In Use | |
| 16571-0817-02 | 16571-0817 | Temozolomide | TEMOZOLOMIDE | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 4, 2022 | In Use | |
| 70518-1398-00 | 70518-1398 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Sep 4, 2018 | In Use | |
| 16714-0027-01 | 16714-0027 | Irinotecan hydrochloride | Irinotecan hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov 15, 2020 | In Use | |
| 71288-0184-05 | 71288-0184 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jun 1, 2025 | In Use | |
| 54868-5447-00 | 54868-5447 | Erlotinib Hydrochloride | Tarceva | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct 13, 2005 | In Use |
Found 12611 results — Export these results
Home